Featured Research

from universities, journals, and other organizations

New Therapy For Patients With Crohn's Disease Identified

Date:
May 4, 2007
Source:
Mayo Clinic
Summary:
A study led by Mayo Clinic found that adalimumab ((HUMIRA) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE)) therapy.

 A study led by Mayo Clinic found that adalimumab (HUMIRA®)) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE®) therapy.

Crohn's disease is an inflammatory disorder of the gastrointestinal tract that affects an estimated 500,000 people in the United States. Symptoms include abdominal pain, fever, nausea, vomiting, weight loss and diarrhea. Crohn's disease has no known medical cure. One common therapy is a series of intravenous infusions of infliximab, which blocks tumor necrosis factor, an important cause of inflammation in Crohn's disease.

"Approximately 50 percent of Crohn's disease patients who receive repeated administration of infliximab will eventually develop an allergic reaction, need higher doses, or completely stop responding to the therapy," says William J. Sandborn, M.D., the lead author and a gastroenterologist at Mayo Clinic. "Our goal with this study was to determine if adalimumab was a safe and effective alternative for these patients."

Like infliximab, adalimumab is a human monoclonal antibody that blocks tumor necrosis factor. However, it is administered via a series of subcutaneous injections, rather than intravenously.

The study included 325 patients at 52 sites with moderate to severe Crohn's disease who continued to have symptoms despite infliximab therapy or who could not take infliximab due to an allergic reaction. Researchers found that 21 percent of patients who received adalimumab achieved remission after four weeks, while just 7 percent of patients who received a placebo achieved remission in the same period. Fifty-two percent of patients who received adalimumab achieved an improvement in their clinical symptoms as compared with 34 percent of patients who received a placebo.

"This study demonstrates that in the short term, adalimumab can be safely administered to Crohn's disease patients who are intolerant of infliximab," says Dr. Sandborn. "For those patients, this new therapy is a second chance at remission and a significant improvement in quality of life."

Patients in this study were recruited from tertiary care centers, academic medical institutions and independent research organizations in the United States, Canada and Europe. These findings were published online  by Annals of Internal Medicine.

This research was funded by Abbott Laboratories. Mayo Clinic receives consulting fees from Abbott Laboratories and Centocor, Inc. for work performed by Dr. Sandborn. Humira (adalimumab) is a product of Abbott Laboratories. Remicade (infliximab) is a product of Centocor, Inc.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "New Therapy For Patients With Crohn's Disease Identified." ScienceDaily. ScienceDaily, 4 May 2007. <www.sciencedaily.com/releases/2007/05/070501115032.htm>.
Mayo Clinic. (2007, May 4). New Therapy For Patients With Crohn's Disease Identified. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2007/05/070501115032.htm
Mayo Clinic. "New Therapy For Patients With Crohn's Disease Identified." ScienceDaily. www.sciencedaily.com/releases/2007/05/070501115032.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) — Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) — Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) — Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins